Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910506949> ?p ?o ?g. }
- W2910506949 endingPage "221" @default.
- W2910506949 startingPage "199" @default.
- W2910506949 abstract "In normal and cancer cells, successful cell division requires accurate duplication of chromosomal DNA. All cells require a multiprotein DNA duplication system (replisomes) for their existence. However, death of normal cells in our body occurs through the apoptotic process. During apoptotic process several crucial genes are downregulated with the upregulation of caspase pathways, leading to ultimate degradation of genomic DNA. In metastatic cancer cells (SKBR-3, MCF -7, and MDA-462), this process is inhibited to achieve immortality as well as overexpression of the enzymes for the synthesis of marker molecules. It is believed that the GSL of the lacto family such as LeX, SA-LeX, LeY, Lea, and Leb are markers on the human colon and breast cancer cells. Recently, we have characterized that a few apoptotic chemicals (cis-platin, L-PPMP, D-PDMP, GD3 ganglioside, GD1b ganglioside, betulinic acid, tamoxifen, and melphalan) in low doses kill metastatic breast cancer cells. The apoptosis-inducing agent (e.g., cis-platin) showed inhibition of DNA polymerase/helicase (part of the replisomes) and also modulated (positively) a few glycolipid-glycosyltransferase (GSL-GLTs) transcriptions in the early stages (within 2 h after treatment) of apoptosis. These Lc-family GSLs are also present on the surfaces of human breast and colon carcinoma cells. It is advantageous to deliver these apoptotic chemicals through the metastatic cell surfaces containing high concentration of marker glycolipids (Lc-GSLs). Targeted application of apoptotic chemicals (in micro scale) to kill the cancer cells would be an ideal way to inhibit the metastatic growth of both breast and colon cancer cells. It was observed in three different breast cancer lines (SKBR-3, MDA-468, and MCF-7) that in 2 h very little apoptotic process had started, but predominant biochemical changes (including inactivation of replisomes) started between 6 and 24 h of the drug treatments. The contents of replisomes (replisomal complexes) during induction of apoptosis are not known. It is known that DNA helicase activities (major proteins catalyze the melting of dsDNA strands) change during apoptotic induction process. Previously DNA Helicase-III was characterized as a component of the replication complexes isolated from carcinoma cells and normal rapid growing embryonic chicken brain cells. Helicase activities were assayed by a novel method (combined immunoprecipitation-ROME assay), and DNA polymerase-alpha activities were determined by regular chain extension of nicked ACT-DNA, by determining values obtained from +/- aphidicolin added to the incubation mixtures. Very little is known about the stability of the replication complexes (or replisomes) during the apoptotic process. DNA helicases are motor proteins that catalyze the melting of genomic DNA during replication, repair, and recombination processes. In all three breast carcinoma cell lines (SKBR-3, MCF-7, and MDA-468), a common trend, decrease of activities of DNA polymerase-alpha and Helicase-III (estimated and detected with a polyclonal antibody), was observed, after cis-platin- and L-PPMP-induced apoptosis. Previously our laboratory has documented downregulation (within 24-48 h) of several GSL-GLTs with these apoptotic reagents in breast and colon cancer cells also. Perhaps induced apoptosis would improve the prognosis in metastatic breast and colon cancer patients." @default.
- W2910506949 created "2019-01-25" @default.
- W2910506949 creator A5005679928 @default.
- W2910506949 creator A5022495163 @default.
- W2910506949 creator A5023350983 @default.
- W2910506949 creator A5037131314 @default.
- W2910506949 creator A5039689547 @default.
- W2910506949 creator A5053056924 @default.
- W2910506949 creator A5075546579 @default.
- W2910506949 creator A5077129710 @default.
- W2910506949 date "2018-01-01" @default.
- W2910506949 modified "2023-10-16" @default.
- W2910506949 title "Induction of Apoptosis in Metastatic Breast Cancer Cells: XV. Downregulation of DNA Polymerase-α – Helicase Complex (Replisomes) and Glyco-Genes" @default.
- W2910506949 cites W142053782 @default.
- W2910506949 cites W1484664508 @default.
- W2910506949 cites W1501269279 @default.
- W2910506949 cites W1514376968 @default.
- W2910506949 cites W1519217994 @default.
- W2910506949 cites W1523846421 @default.
- W2910506949 cites W1528476635 @default.
- W2910506949 cites W1546095443 @default.
- W2910506949 cites W1560152642 @default.
- W2910506949 cites W1579328338 @default.
- W2910506949 cites W1603167745 @default.
- W2910506949 cites W1603564685 @default.
- W2910506949 cites W1626070385 @default.
- W2910506949 cites W1634238805 @default.
- W2910506949 cites W1671589314 @default.
- W2910506949 cites W1673478505 @default.
- W2910506949 cites W173312200 @default.
- W2910506949 cites W1912592927 @default.
- W2910506949 cites W1965264969 @default.
- W2910506949 cites W1968074226 @default.
- W2910506949 cites W1969963076 @default.
- W2910506949 cites W1972164756 @default.
- W2910506949 cites W1974394081 @default.
- W2910506949 cites W1976254818 @default.
- W2910506949 cites W1980411311 @default.
- W2910506949 cites W1982205851 @default.
- W2910506949 cites W1984853096 @default.
- W2910506949 cites W1987639811 @default.
- W2910506949 cites W1996630968 @default.
- W2910506949 cites W1997897583 @default.
- W2910506949 cites W2006110768 @default.
- W2910506949 cites W2008688413 @default.
- W2910506949 cites W2009430092 @default.
- W2910506949 cites W2009775819 @default.
- W2910506949 cites W2010731942 @default.
- W2910506949 cites W2010853485 @default.
- W2910506949 cites W2012108057 @default.
- W2910506949 cites W2013176968 @default.
- W2910506949 cites W2015631309 @default.
- W2910506949 cites W2016327026 @default.
- W2910506949 cites W2017174588 @default.
- W2910506949 cites W2024342621 @default.
- W2910506949 cites W2028161508 @default.
- W2910506949 cites W2038692966 @default.
- W2910506949 cites W2039584375 @default.
- W2910506949 cites W2040860790 @default.
- W2910506949 cites W2043513943 @default.
- W2910506949 cites W2046445536 @default.
- W2910506949 cites W2055869110 @default.
- W2910506949 cites W2058854434 @default.
- W2910506949 cites W2060584044 @default.
- W2910506949 cites W2061754995 @default.
- W2910506949 cites W2065706535 @default.
- W2910506949 cites W2076179928 @default.
- W2910506949 cites W2076694000 @default.
- W2910506949 cites W2082264358 @default.
- W2910506949 cites W2084609653 @default.
- W2910506949 cites W2087379950 @default.
- W2910506949 cites W2087547475 @default.
- W2910506949 cites W2103646786 @default.
- W2910506949 cites W2104247890 @default.
- W2910506949 cites W2108780687 @default.
- W2910506949 cites W2114132032 @default.
- W2910506949 cites W2121777852 @default.
- W2910506949 cites W2124312551 @default.
- W2910506949 cites W2132546148 @default.
- W2910506949 cites W2135015314 @default.
- W2910506949 cites W2136511531 @default.
- W2910506949 cites W2157930185 @default.
- W2910506949 cites W2162424511 @default.
- W2910506949 cites W2168458938 @default.
- W2910506949 cites W2170326957 @default.
- W2910506949 cites W2196646621 @default.
- W2910506949 cites W2500588224 @default.
- W2910506949 cites W2551179784 @default.
- W2910506949 cites W2594057051 @default.
- W2910506949 cites W4239718055 @default.
- W2910506949 cites W80744218 @default.
- W2910506949 doi "https://doi.org/10.1007/978-981-13-3065-0_15" @default.
- W2910506949 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30637700" @default.
- W2910506949 hasPublicationYear "2018" @default.
- W2910506949 type Work @default.
- W2910506949 sameAs 2910506949 @default.
- W2910506949 citedByCount "1" @default.
- W2910506949 countsByYear W29105069492021 @default.